Abstract
The in vitro susceptibilities of 10 strains of Chlamydia pneumoniae were determined for five quinolones, including ciprofloxacin, ofloxacin, fleroxacin, temafloxacin, and sparfloxacin. Sparfloxacin was the most active compound tested, followed by ofloxacin and temafloxacin. Ciprofloxacin and fleroxacin were the least active. The use of HEp-2 cells for testing C. pneumoniae resulted in larger inclusions but essentially the same endpoints as were seen with use of HeLa 229 cells.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Chirgwin K., Roblin P. M., Gelling M., Hammerschlag M. R., Schachter J. Infection with Chlamydia pneumoniae in Brooklyn. J Infect Dis. 1991 Apr;163(4):757–761. doi: 10.1093/infdis/163.4.757. [DOI] [PubMed] [Google Scholar]
- Chirgwin K., Roblin P. M., Hammerschlag M. R. In vitro susceptibilities of Chlamydia pneumoniae (Chlamydia sp. strain TWAR). Antimicrob Agents Chemother. 1989 Sep;33(9):1634–1635. doi: 10.1128/aac.33.9.1634. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ehret J. M., Judson F. N. Susceptibility testing of Chlamydia trachomatis: from eggs to monoclonal antibodies. Antimicrob Agents Chemother. 1988 Sep;32(9):1295–1299. doi: 10.1128/aac.32.9.1295. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gerding D. N., Hitt J. A. Tissue penetration of the new quinolones in humans. Rev Infect Dis. 1989 Jul-Aug;11 (Suppl 5):S1046–S1057. doi: 10.1093/clinids/11.supplement_5.s1046. [DOI] [PubMed] [Google Scholar]
- Grayston J. T., Campbell L. A., Kuo C. C., Mordhorst C. H., Saikku P., Thom D. H., Wang S. P. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J Infect Dis. 1990 Apr;161(4):618–625. doi: 10.1093/infdis/161.4.618. [DOI] [PubMed] [Google Scholar]
- Hammerschlag M. R., Chirgwin K., Roblin P. M., Gelling M., Dumornay W., Mandel L., Smith P., Schachter J. Persistent infection with Chlamydia pneumoniae following acute respiratory illness. Clin Infect Dis. 1992 Jan;14(1):178–182. doi: 10.1093/clinids/14.1.178. [DOI] [PubMed] [Google Scholar]
- Lipsky B. A., Tack K. J., Kuo C. C., Wang S. P., Grayston J. T. Ofloxacin treatment of Chlamydia pneumoniae (strain TWAR) lower respiratory tract infections. Am J Med. 1990 Dec;89(6):722–724. doi: 10.1016/0002-9343(90)90212-v. [DOI] [PubMed] [Google Scholar]
- Segreti J., Hirsch D. J., Harris A. A., Kapell K. S., Orbach H., Kessler H. A. In vitro activity of tosufloxacin (A-61827; T-3262) against selected genital pathogens. Antimicrob Agents Chemother. 1990 Jun;34(6):971–973. doi: 10.1128/aac.34.6.971. [DOI] [PMC free article] [PubMed] [Google Scholar]